Our clinical trials
ICR-CTSU clinical trials focus on breast, urological and head and neck cancers, but we also run trials in other rarer cancer types including melanoma, sarcoma and ovarian cancer.
We specialise in phase II exploratory and phase III randomised trials of new treatments and technologies (including radiotherapy), and understanding cancer biology and treatment response using biomarker-driven trial designs is fundamental to our research.
More information about the different clinical trials we run can be found on the clinical trials pages.
For patients and the public
To find out more about ICR-CTSU research, including how to become involved in clinical trials, please visit our patients and public page. In addition, most clinical trial pages include a link to the study’s plain English summary.
ICR-CTSU is a research-led, academic clinical trials unit (CTU) within the Division of Clinical Studies at the ICR. Our expertise spans the whole clinical trial life cycle. We receive core funding from Cancer Research UK, are a UK Clinical Research Collaborative (UKCRC) registered CTU and one of 15 CTUs recognised by the National Cancer Research Institute (NCRI) for professional specialism in the development and delivery of cancer trials.
ICR-CTSU is committed to the responsible sharing of clinical trial data and trial samples with the wider research community in order to improve scientific and medical knowledge about cancer. To enable data and samples to be effectively shared with others, an access policy and defined procedure exist to ensure that relevant legal, ethical and commercial constraints are recognised and that data and samples are made available for new research purposes in a responsible manner. Please consult the data sharing page for further information.
If you are interested in working with us, please visit our collaborators’ page or explore current ICR vacancies.